CSL sinks to nine-year low on revenue warning, $5B write-down
CSL Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
CSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by about 4% and said it would have to take a new $5 billion impairment charge.
The ...
Source: Endpoints News